



Sunday 4 December, 12.00–13.30

CURRENT AND EMERGING TREATMENTS FOR PATIENTS WITH ALK+ NSCLC

Strauss 3, Messe Wien Exhibition & Congress Center
Vienna, Austria

Lunch will be provided

CURRENT AND EMERGING TREATMENTS FOR PATIENTS WITH ALK+ NSCLC

FACULTY

Co-chairs

Christoph Zielinski, MD, PhD

Medical University Vienna,
Vienna, Austria

D. Ross Camidge, MD, PhD

University of Colorado School of Medicine,
Aurora, CO, USA

Pasi A. Jänne, MD, PhD

Dana Farber Cancer Institute,
Boston, MA, USA

AGENDA

TIME	PRESENTATION	PRESENTER
12.00	Welcome and introduction	Christoph Zielinski, MD, PhD D. Ross Camidge, MD, PhD
12.05	ALK inhibitors: current treatments and sequencing	Christoph Zielinski, MD, PhD
12.20	Q&A panel discussion	All
12.30	The future of ALK inhibitors: how the treatment paradigm may change	D. Ross Camidge, MD, PhD
12.45	Q&A panel discussion	All
12.55	Will mutation testing be standard in the resistant setting?	Pasi A. Jänne, MD, PhD
13.10	Q&A panel discussion	All
13.20	Summary and conclusions	Christoph Zielinski, MD, PhD D. Ross Camidge, MD, PhD



This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.